FCMI
EPZM

Foresite Capital Management I’s Epizyme, Inc EPZM Stock Holding History

Foresite Capital Management I’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-143,759
Closed -$165K – 2
2022
Q1 		$165K Hold
143,759
– – 0.29% 2
2021
Q4 		$359K Sell
143,759
-150,000
-51% -$589K 0.32% 2
2021
Q3 		$1.5M Hold
293,759
– – 1.18% 4
2021
Q2 		$2.44M Hold
293,759
– – 1.47% 3
2021
Q1 		$2.56M Hold
293,759
– – 1.29% 4
2020
Q4 		$3.19M Buy
293,759
+50,000
+21% +$617K 1.68% 3
2020
Q3 		$2.91M Hold
243,759
– – 0.82% 3
2020
Q2 		$3.92M Buy
+243,759
New +$4.25M 1.23% 2

Other funds holding EPZM

RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Foresite Capital Management I's EPZM Position: Q2 2022 in Review

Foresite Capital Management I sold out of Epizyme, Inc (EPZM) in Q2 2022, closing a stake of 143,759 shares — an estimated $165K sold.

Foresite Capital Management I first reported a position in EPZM in Q2 2020 and held it in 8 quarters. The position peaked at $3.92M in Q2 2020. 93 funds tracked by Wall St. Rank hold EPZM as of Q2 2022.

  • Foresite Capital Management I reported no remaining Epizyme, Inc position as of Q2 2022 after selling out during the quarter.
  • Foresite Capital Management I sold 143,759 Epizyme, Inc shares in Q2 2022, an estimated $165K.
  • Foresite Capital Management I first reported a position in Epizyme, Inc in Q2 2020 and held it in 8 quarters.
  • Foresite Capital Management I's Epizyme, Inc position peaked at $3.92M in Q2 2020.
  • 93 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2022.

Based on Foresite Capital Management I's 13F filing for Q2 2022, filed 12 Aug 2022.